BL Pharmtech Statistics

Total Valuation

BL Pharmtech has a market cap or net worth of KRW 23.72 billion. The enterprise value is 26.28 billion.

Market Cap	23.72B
Enterprise Value	26.28B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

BL Pharmtech has 26.68 million shares outstanding. The number of shares has decreased by -0.38% in one year.

Current Share Class	26.68M
Shares Outstanding	26.68M
Shares Change (YoY)	-0.38%
Shares Change (QoQ)	-0.04%
Owned by Insiders (%)	27.53%
Owned by Institutions (%)	n/a
Float	19.33M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.85
PB Ratio	1.03
P/TBV Ratio	1.04
P/FCF Ratio	18.78
P/OCF Ratio	17.82
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.79
EV / Sales	3.15
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	20.81

Financial Position

The company has a current ratio of 0.83, with a Debt / Equity ratio of 0.27.

Current Ratio	0.83
Quick Ratio	0.45
Debt / Equity	0.27
Debt / EBITDA	n/a
Debt / FCF	4.88
Interest Coverage	-4.36

Financial Efficiency

Return on equity (ROE) is -20.19% and return on invested capital (ROIC) is -7.66%.

Return on Equity (ROE)	-20.19%
Return on Assets (ROA)	-6.29%
Return on Invested Capital (ROIC)	-7.66%
Return on Capital Employed (ROCE)	-14.53%
Revenue Per Employee	694.46M
Profits Per Employee	-457.20M
Employee Count	12
Asset Turnover	0.21
Inventory Turnover	2.37

Taxes

Income Tax	-51.83M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -54.32% in the last 52 weeks. The beta is 0.55, so BL Pharmtech's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	-54.32%
50-Day Moving Average	931.70
200-Day Moving Average	1,081.37
Relative Strength Index (RSI)	33.61
Average Volume (20 Days)	106,493

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BL Pharmtech had revenue of KRW 8.33 billion and -5.49 billion in losses. Loss per share was -205.58.

Revenue	8.33B
Gross Profit	5.50B
Operating Income	-3.97B
Pretax Income	-5.55B
Net Income	-5.49B
EBITDA	-3.12B
EBIT	-3.97B
Loss Per Share	-205.58

Full Income Statement

Balance Sheet

The company has 3.62 billion in cash and 6.16 billion in debt, giving a net cash position of -2.54 billion or -95.28 per share.

Cash & Cash Equivalents	3.62B
Total Debt	6.16B
Net Cash	-2.54B
Net Cash Per Share	-95.28
Equity (Book Value)	23.08B
Book Value Per Share	864.29
Working Capital	-1.71B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.33 billion and capital expenditures -67.78 million, giving a free cash flow of 1.26 billion.

Operating Cash Flow	1.33B
Capital Expenditures	-67.78M
Free Cash Flow	1.26B
FCF Per Share	47.34

Full Cash Flow Statement

Margins

Gross margin is 66.02%, with operating and profit margins of -47.62% and -65.84%.

Gross Margin	66.02%
Operating Margin	-47.62%
Pretax Margin	-66.63%
Profit Margin	-65.84%
EBITDA Margin	-37.41%
EBIT Margin	-47.62%
FCF Margin	15.15%

Dividends & Yields

BL Pharmtech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.38%
Shareholder Yield	n/a
Earnings Yield	-23.13%
FCF Yield	5.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 26, 2025. It was a forward split with a ratio of 3.

Last Split Date	Feb 26, 2025
Split Type	Forward
Split Ratio	3

Scores

BL Pharmtech has an Altman Z-Score of -1.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.27
Piotroski F-Score	3